The Best Muscle Building & Fat Loss Peptide | TB-500 (Thymosin Beta 4) Benefits & Risks
A solo explainer in which DeLauer walks through preclinical and early research on TB-500 (thymosin beta 4) for injury, brain, heart and muscle, plus his safety caveats.
Key moments
Tap a moment to play the video from there.
- 0:00What TB-500 isDeLauer introduces TB-500 as the synthetic version of thymosin beta 4 and describes peptides as chains of amino acids. He says the thymus releases it in response to injury.
- 1:00His own experience and disclaimerHe describes using TB-500 with BPC-157 for a labrum issue and torn rotator cuff and says he has no stake in a peptide company. He urges viewers to consult a healthcare professional.
- 2:25Declining levels and purported benefitsHe says natural production appears to fall with age and that TB-500 is meant to supply a larger dose. He stresses the benefits are purported because human data is scarce.
- 3:05Ligament and wound repair studiesHe cites a preclinical ligament study and a wound study, describing denser collagen, restored biomechanics, and 42% and 61% more skin and collagen at 4 and 7 days.
- 5:07Sepsis study and inflammationHe describes a preclinical sepsis study with lower mortality and inflammatory signaling, and relates it to his own feeling of less soreness.
- 6:08Brain and neuroinflammation researchHe covers preclinical work on amyloid plaque, neuron function, microglia and inflammation markers. He repeats that none of it is in humans.
- 8:32Heart cells and angiogenesis cautionHe reads from an in vitro heart study, then warns that too much angiogenesis may be unwanted and says he sees no case for ongoing use.
- 10:14Muscle recovery studyHe describes a preclinical study in a muscle-repair deficiency model dosed at 150 micrograms twice a week for 6 months. He says it showed more regenerating fibers and that human translation is unproven.
- 12:02Side effects and safety studyHe lists headache, nausea and post-exercise fatigue as reported effects and cites a 30-person study that found minimal side effects. He recommends consulting a professional.
What the video says
Thomas DeLauer presents TB-500, the synthetic form of thymosin beta 4, a peptide he says the thymus releases in response to injury and produces less of with age. He explains peptides as short chains of amino acids that mimic signals in the body. He shares that he used TB-500 alongside BPC-157 for a labrum problem and a torn rotator cuff, says a couple of weeks was enough for him, and states he has no stake in any peptide company. He tells viewers to speak with a healthcare professional. A short sponsor segment for a grocery delivery service sits near the start.
DeLauer repeatedly calls the benefits purported because he says there is very little human data. For injury, he cites a preclinical ligament study using 1 microgram daily for 4 weeks, which he says produced denser, evenly spaced collagen fibers and better restored biomechanics. He also cites a wound study reporting 42% more skin and collagen coverage at 4 days and 61% at 7 days, and a preclinical sepsis study with lower mortality and lower inflammatory signaling. He links these to angiogenesis and collagen deposition, and adds his own impression of less soreness and better heart rate variability.
He then moves to more speculative areas. In preclinical work where animals were made to overproduce thymosin beta 4, he says amyloid plaque formation fell, neuron function improved, microglia activity returned toward normal, and inflammation markers dropped. He reads a quote from an in vitro heart study describing simultaneous heart muscle and blood vessel regeneration. He cautions that too much angiogenesis may be a problem, says Andrew Huberman voiced the same concern to him, and says he sees no practical case for ongoing use of BPC-157 or TB-500. For muscle, he describes a preclinical model with a muscle-repair protein deficiency, given 150 micrograms twice a week for 6 months, which showed more regenerating fibers.
On safety, DeLauer says headache and nausea are the most common effects soon after dosing, and some people report unusual tiredness after exercise. He cites a study of 30 people given single and multiple doses that found minimal side effects, enough to support a longer clinical trial. He closes by recommending a professional and names two practitioners he follows.
On each compound
TB-5002:25
DeLauer presents TB-500 as the synthetic form of thymosin beta 4 and cites preclinical and in vitro studies on tissue repair, brain inflammation, heart cells and muscle. He says human evidence is thin and reports headache, nausea and post-exercise fatigue as side effects.
See how your DNA reads TB-500BPC-1571:00
DeLauer says he used BPC-157 together with TB-500 for his own shoulder and labrum injuries. He also says he does not see a practical case for ongoing use of BPC-157 or similar angiogenesis-promoting peptides.
See how your DNA reads BPC-157“too much angiogenesis is not always good”
What this video doesn’t settle
- Nearly all the effects described come from preclinical or in vitro studies, and the video does not show that any of them occur in people.
- DeLauer's account of recovering from his labrum and rotator cuff injuries is one person's experience, with no control group and a second peptide used at the same time.
- The 30-person safety study is described only as single and multi-dose, so the video does not establish long-term safety.
Questions this video answers
What is TB-500 and how is it related to thymosin beta 4?
DeLauer says thymosin beta 4 is a molecule the thymus secretes in response to injury, and TB-500 is the synthetic peptide form of it. He treats the two names as describing the same thing.
What side effects of TB-500 does DeLauer mention?
He says headache and nausea are the most common effects and tend to appear soon after administration. He also says some people report becoming very tired after exercise, though he notes the data is weak.
What research does DeLauer cite on TB-500 and injury recovery?
He cites a preclinical ligament study using 1 microgram daily for 4 weeks, a wound study reporting 42% and 61% more skin and collagen at 4 and 7 days, and a preclinical sepsis study. He says these point to effects on angiogenesis, collagen and inflammation.
Does DeLauer recommend using TB-500 long term?
No. He says he does not see a practical application for ongoing use of BPC-157, TB-500 or similar peptides and suggests short courses only, partly because of concern about excess angiogenesis. He tells viewers to talk to a doctor.
Is there human evidence for TB-500 in this video?
Mostly no. DeLauer says there is very little human data and that most findings come from preclinical or in vitro work. The one human study he cites involved 30 people and looked at safety.
Video by Thomas DeLauer on YouTube, embedded as published. The summary is written by PeptidesDNA from the video; every claim in it is the speaker’s. Not affiliated with or endorsed by the creator. Not medical advice.
